Medicus Pharma Ltd (MDCX) Price & Analysis

Compare

118 Followers

MDCX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.79 - $8.94

Previous CloseN/A

Volume5.92K

Average Volume (3M)429.94K

Market Cap

$49.52M

Enterprise Value$38.01M

Total Cash (Recent Filing)$9.67M

Total Debt (Recent Filing)$4.97M

Price to Earnings (P/E)―

Beta1.30

Next Earnings

Nov 21, 2025

EPS Estimate

-0.29

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.43

Shares Outstanding19,419,430

10 Day Avg. Volume485,394

30 Day Avg. Volume429,942

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.77

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-2.45

Forecast

1Y Price Target

$20.00

Price Target Upside706.45% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Acquisition And Pipeline ExpansionMedicus Pharma Ltd. acquired SkinJect Inc., focusing on commercializing its non-invasive treatment for basal cell carcinoma.

Clinical Trials And International ExpansionMedicus announced the start of a second P2 study in the United Arab Emirates, expanding its clinical trials internationally.

Financial StabilityRecent financing of $7 million provides Medicus with a financial runway extending into the fourth quarter of 2025 or first quarter of 2026.

New Market OpportunitiesThe expansion into equine treatment of squamous cell carcinoma could represent a significant market opportunity, potentially reaching $250 million.

Bears Say

Market ChallengesThe slow erosion in the stock over the last few months is believed to stem from a lack of significant catalysts amid challenging biotech markets, particularly for microcaps.

Pipeline Progress UncertaintyThe ongoing Phase 2 SkinJect trial in nodular basal cell carcinoma has enrolled over 75% of the planned patients, with FDA feedback on a potential pivotal path expected soon.

Medicus Pharma Ltd News

Medicus Pharma price target raised to $20 from $12 at Brookline

Brookline raised the firm’s price target on Medicus Pharma (MDCX) to $20 from $12 and keeps a Buy...

3d ago

MDCX

Medicus Pharma announces $8M debenture financing

Medicus Pharma (MDCX) entered into a purchase agreement with YA II PL, pursuant to which the Company has...

9d ago

MDCX

Medicus Pharma says UAE SKNJCT-004 Phase 2 trial commences patient recruitment

Medicus Pharma (MDCX) announced that the SKNJCT-004 phase 2 clinical study, to non-invasively treat BCC of the skin,...

19d ago

MDCX

Medicus Pharma to Present Key Developments at Brookline Capital Markets

An announcement from Medicus Pharma Ltd ( ($MDCX) ) is now available. Medicus Pharma Ltd. is set to...

3d ago

MDCX

Medicus Pharma Secures $8 Million Financing to Advance Teverelix Development

Medicus Pharma Ltd ( ($MDCX) ) has shared an announcement. Medicus Pharma Ltd. has secured an $8 million...

9d ago

MDCX

Medicus Pharma Ltd: Promising Developments and Strategic Expansions Drive Buy Rating

Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Medicus Pharma Ltd and keeping the price...

10d ago

MDCX

Medicus Pharma Appoints Carolyn Bonner as Acting CFO

Medicus Pharma Ltd ( ($MDCX) ) has shared an update. On September 12, 2025, Medicus Pharma Ltd. announced...

15d ago

MDCX

Medicus Pharma Ltd. Acquires Antev Limited, Expanding Drug Development Pipeline

Medicus Pharma Ltd ( ($MDCX) ) has provided an announcement. Medicus Pharma Ltd. has completed the acquisition of...

16d ago

MDCX

Medicus Pharma Ltd. Advances Clinical Trials for Skin Cancer Treatment

Medicus Pharma Ltd ( ($MDCX) ) has issued an announcement. Medicus Pharma Ltd. announced the commencement of patient...

17d ago

MDCX

Medicus Pharma Ltd. Advances Clinical Trials for Skin Cancer Treatment

Medicus Pharma Ltd ( ($MDCX) ) has issued an announcement. Medicus Pharma Ltd. announced the commencement of patient...

19d ago

MDCX

Medicus Pharma Ltd. Acquires Antev Limited, Expanding Drug Development Pipeline

Medicus Pharma Ltd ( ($MDCX) ) has provided an announcement. Medicus Pharma Ltd. has completed the acquisition of...

25d ago

MDCX

Medicus Pharma Completes Equity Sales to Yorkville

An update from Medicus Pharma Ltd ( ($MDCX) ) is now available. Medicus Pharma Ltd. announced the completion...

1M ago

MDCX

Medicus Pharma Advances D-MNA Clinical Program and Expands Strategic Partnerships

Medicus Pharma Ltd ( ($MDCX) ) has provided an update. Medicus Pharma Ltd. announced that the FDA has...

1M ago

MDCX

Medicus Pharma management to meet with Maxim

Meeting to be held on June 25 hosted by Maxim. Published first on TheFly – the ultimate source...

3M ago

MDCX

MDCX FAQ

What was Medicus Pharma Ltd’s price range in the past 12 months?

Medicus Pharma Ltd lowest stock price was $1.79 and its highest was $8.94 in the past 12 months.

What is Medicus Pharma Ltd’s market cap?

Medicus Pharma Ltd’s market cap is $49.52M.

When is Medicus Pharma Ltd’s upcoming earnings report date?

Medicus Pharma Ltd’s upcoming earnings report date is Nov 21, 2025 which is in 55 days.

How were Medicus Pharma Ltd’s earnings last quarter?

Medicus Pharma Ltd released its earnings results on Aug 12, 2025. The company reported -$0.43 earnings per share for the quarter, missing the consensus estimate of -$0.25 by -$0.18.

Is Medicus Pharma Ltd overvalued?

According to Wall Street analysts Medicus Pharma Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Medicus Pharma Ltd pay dividends?

Medicus Pharma Ltd does not currently pay dividends.

What is Medicus Pharma Ltd’s EPS estimate?

Medicus Pharma Ltd’s EPS estimate is -0.29.

How many shares outstanding does Medicus Pharma Ltd have?

Medicus Pharma Ltd has 19,419,430 shares outstanding.

What happened to Medicus Pharma Ltd’s price movement after its last earnings report?

Medicus Pharma Ltd reported an EPS of -$0.43 in its last earnings report, missing expectations of -$0.25. Following the earnings report the stock price went up 13.706%.

Which hedge fund is a major shareholder of Medicus Pharma Ltd?

Currently, no hedge funds are holding shares in MDCX

Medicus Pharma Ltd Stock Smart Score

Underperform

Fundamentals

Return on Equity

-340.46%

Trailing 12-Months

Asset Growth

35.91%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Medicus Pharma Ltd

Medicus Pharma Ltd (MDCX) is a pharmaceutical company specializing in the research, development, and commercialization of innovative medicines and healthcare solutions. The company operates within the pharmaceutical and biotechnology sectors, focusing on a diverse range of therapeutic areas including oncology, cardiovascular diseases, and immunology. Medicus Pharma Ltd is committed to improving patient outcomes through advanced drug therapies and cutting-edge research.

Medicus Pharma Ltd (MDCX) Earnings & Revenues

Historic Earnings Reports

MDCX Stock 12 Month Forecast

Average Price Target

$20.00

▲(706.45% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","6":"$6","11":"$11","16":"$16","21":"$21"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,6,11,16,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.08,3.4584615384615387,4.836923076923077,6.215384615384616,7.593846153846155,8.972307692307693,10.350769230769233,11.729230769230771,13.107692307692309,14.486153846153847,15.864615384615385,17.243076923076927,18.621538461538464,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.08,3.4584615384615387,4.836923076923077,6.215384615384616,7.593846153846155,8.972307692307693,10.350769230769233,11.729230769230771,13.107692307692309,14.486153846153847,15.864615384615385,17.243076923076927,18.621538461538464,{"y":20,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.08,3.4584615384615387,4.836923076923077,6.215384615384616,7.593846153846155,8.972307692307693,10.350769230769233,11.729230769230771,13.107692307692309,14.486153846153847,15.864615384615385,17.243076923076927,18.621538461538464,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.3,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.54,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.4,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.44,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.56,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.46,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.46,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.6,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.99,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.96,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.32,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.95,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.08,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >